Comparing characteristics between patients with a reactive versus non-reactive STAT-VIEW rapid test during acute HIV infection
| N | Total (n=40) | STAT-VIEW | p* | INSTI | p* | |||
| Reactive (n=23) | Non-reactive (n=17) | Reactive(n=25) | Non-reactive (n=15) | |||||
| Age, years† | 40 | 36 (29–44) | 39 (28–44) | 32 (30–47) | 0.9 | 39 (28–44) | 35 (30–47) | 0.9 |
| Time since infection, days† | 37 | 25 (20–36) | 31 (23–40) | 22 (17–30) | 0.01 | 30 (23–39) | 20 (17–25) | 0.007 |
| Symptomatic acute illness‡ | 40 | 35 (87.5) | 20 (87.0) | 15 (88.2) | 0.9 | 22 (88.0) | 13 (86.7) | 0.9 |
| Time since onset of symptoms, days†§ | 35 | 15 (7–26) | 19 (14–27) | 8 (5–15) | 0.009 | 16 (12–26) | 8 (5–19) | 0.15 |
| Hospitalisation due to HIV-related symptoms‡ | 40 | 6 (15) | 2 (8.7) | 4 (23.5) | 0.4 | 2 (8.0) | 4 (26.7) | 0.17 |
| HIV serological result, S/CO† | 40 | 38.5 (19.2–89.1) | 44.0 (21.6–87.7) | 24.6 (10.5–104.2) | 0.6 | 47.2 (21.6–87.7) | 24.6 (10.2–220.1) | 0.5 |
| Detectable p24‡ | 99 | 27 (93.1) | 13 (92.9) | 14 (93.3) | 0.9 | 14 (93.3) | 12 (929) | 0.9 |
| p24 level† | 27 | 250 (135–250) | 151 (53–250) | 250 (250–300) | 0.07 | 215 (53–250) | 250 (200–250) | 0.4 |
| Western blot result‡ | 40 | <0.001 | 0.007 | |||||
| Indeterminate‡ | 33 (82.5) | 23 (100) | 10 (58.8) | 24 (96.0) | 9 (60.0) | |||
| Negative‡ | 7 (17.5) | 0 | 7 (41.2) | 1 (4.0) | 6 (40.0) | |||
| HIV-RNA viral load (log10 copies/mL)† | 39 | 5.95 (5.70–6.86) | 5.74 (5.48–5.95) | 6.84 (6.10–7.00) | 0.001 | 5.75 (5.58–6.44) | 6.52 (5.81–7.00) | 0.01 |
| CD4+ T cell count, /mm3† | 38 | 441 (367–520) | 481 (381–593) | 383 (240–504) | 0.03 | 484 (382–585) | 381 (249–467) | 0.02 |
| CD8+ T cell count, /mm3† | 38 | 676 (486–1215) | 1073 (675–1462) | 443 (322–532) | <0.001 | 964 (610–1403) | 494 (371–663) | 0.002 |
| CD4:CD8 ratio† | 38 | 0.65 (0.36–0.80) | 0.42 (0.31–0.71) | 0.79 (0.69–1.22) | 0.001 | 0.49 (0.34–0.76) | 0.78 (0.65–1.17) | 0.04 |
| Fiebig stageঠ| 40 | 0.003 | 0.02 | |||||
| III‡ | 6 (15.0) | 0 | 6 (35.3) | 1 (4.0) | 5 (33.3) | |||
| IV‡ | 34 (85.0) | 23 (100) | 11 (64.7) | 24 (96.0) | 10 (66.7) | |||
| HIV non-B subtype‡ | 39 | 14 (35.9) | 7 (30.4) | 7 (43.8) | 0.3 | 6 (24.0) | 8 (57.1) | 0.04 |
*Significance between reactive groups determined using Kruskal-Wallis test for continuous variables and Pearson χ² test or Fisher’s exact test for categorical variables.
†Median (IQR).
‡n (%).
§Only for symptomatic patients.
¶Fiebig stages are as follows: I: HIV plasma RNA+, p24 Ag−, HIV Ag/Ab ELISA assay (HIV Ag/Ab)−; II: HIV-RNA+, p24 Ag+, HIV Ag/Ab−; III: HIV-RNA+, p24 Ag−, HIV Ag/Ab+, western blot (WB)−; IV: HIV-RNA+, p24 Ag−, HIV Ag/Ab+, WB indeterminate; V: HIV-RNA+, p24 Ag−, HIV Ag/Ab+, WB+, p31−; VI: HIV-RNA+, p24 Ag−, HIV Ag/Ab+, WB +with p31+.8